CustomCustomCustomCustomCustomCustom
21 09, 2023

Unique miRNome and transcriptome profiles underlie microvascular heterogeneity in mouse kidney

2023-09-21T11:12:47+02:00September 21st, 2023|biomarker, biomarkers, LMD, microRNA services, microRNAs, microstructure, NGS, Vivomicx|Comments Off on Unique miRNome and transcriptome profiles underlie microvascular heterogeneity in mouse kidney

We want to draw your attention to our latest publication which appeared in American Journal of Physiology-Renal Physiology. We could show that laser microdissection combined with (small) RNA sequencing revealed renal microvascular compartment-specific miRNA and mRNA expression profiles. Unique miRNome and transcriptome profiles underlie microvascular heterogeneity in mouse kidney Luxen M, Zwiers PJ, Meester F et al. Am J Physiol Renal Physiol. 2023 Sep 1;325(3):F299-F316. doi: 10.1152/ajprenal.00005.2023. Epub 2023 Jul 6. TAmiRNA and Dutch company Vivomicx have combined their respective technologies of high sensitivity gene expression profiling (RT-qPCR and smallRNAseq/RNAseq) and laser microdissection to enable cell-type specific and space-resolved RNA expression analysis in complex tissues. Click here to learn more about this service

Read More
26 05, 2022

hepatomiR kit

2023-03-10T10:14:05+01:00May 26th, 2022|biomarkers, hepatomiR kit, Liver disease, microRNA|Comments Off on hepatomiR kit

TAmiRNA has launched its latest hepatomiR® CE-IVD testing kit that can measure levels of three important liver-enriched microRNAs (liver miRNAs) in human blood to determine a patient’s liver function. TAmiRNA’s microRNA-based hepatomiR® kit is worldwide the first approved CE-IVD test to measure microRNA liver biomarkers in human plasma. The new microRNA-based hepatomiR® technology represents a milestone previously restricted to research use only (RUO) testing. click here for more Information on the hepatomiR-kit

Read More
2 03, 2022

miRNA NGS Discovery pipeline – miND

2023-03-10T10:13:34+01:00March 2nd, 2022|biomarkers, microRNA, NGS|Comments Off on miRNA NGS Discovery pipeline – miND

TAmiRNA present microRNA Next-Generation-Sequencing Discovery Assay (miND), a novel panel of exogenous small RNA spike-in controls that enables quality control and absolute quantitation of NGS data. Eager to learn more - have a look at our two new publications! click here for more Information on the novel wet-lab small RNA-seq workflow and here for more insights into the bioinformatic pipeline

Read More
9 04, 2021

TAmiRNA shares microRNA biomarker insights at FIDELIO training webinar

2023-03-10T10:19:36+01:00April 9th, 2021|aging, biomarker, biomarkers, bone diseases, bone fracture risk assessment, diabetes, microRNAs, microstructure, osteoporosis, Personalized medicine, type 2 diabetes mellitus|Comments Off on TAmiRNA shares microRNA biomarker insights at FIDELIO training webinar

TAmiRNA is a key partner in the EU-funded Innovative Training Network FIDELIO, which aims to train the next generation of scientists in tackling the challenges of bone fragility in diabetic patients. The  webinar "MicroRNAs: small RNAs with big potential as biomarkers and drug targets in bone diseases" is a one-hour session hosted by TAmiRNA founder and CEO Dr. Matthias Hackl. He show how microRNAs control gene expression in virtually all human cells and that miRNA expression changes during the onset and progression of (bone) disorders enabling applications as biomarkers and drug targets. He introduce the biological and methodical basics of microRNA research and discuss diagnostic and therapeutic applications of microRNAs in bone disease. [...]

Read More
19 01, 2021

Circulating miRNAs in bone health and disease

2023-03-10T11:38:55+01:00January 19th, 2021|aging, biomarker, biomarkers, bone diseases, bone fracture risk assessment, microRNAs, microstructure, osteoporosis, Personalized medicine|Comments Off on Circulating miRNAs in bone health and disease

We want to draw your attention to our latest review which appeared in the special issue on miRNAs in Bone Research in Bone. In this review, we summarize important molecular basics of microRNA function and release and provide recommendations for best (pre-)analytical practices and documentation standards for circulating microRNA research required for generating high quality data and ensuring reproducibility of results. We review how the genesis of bone-derived circulating microRNAs via release from osteoblasts and osteoclasts could contribute to the communication between these cells and summarize evidence from clinical research studies that have investigated the clinical utility of microRNAs as biomarkers in musculoskeletal disorders. While previous reviews have mainly focused on diagnosis of primary osteoporosis, we have [...]

Read More
24 11, 2020

microRNA-146a controls age-related bone loss

2023-03-10T10:21:20+01:00November 24th, 2020|aging, biomarker, biomarkers, bone diseases, bone fracture risk assessment, microRNAs, microstructure, osteoporosis, Personalized medicine|Comments Off on microRNA-146a controls age-related bone loss

We want to draw your attention to the latest publication in cooperation with TAmiRNA. The study identifies a novel and unexpected role of miR‐146a in bone homeostasis. miR‐146a increases with age and acts as an epigenetic molecular switch terminating bone accrual, leading to bone loss during aging by downregulating bone anabolic Wnt signaling. Conversely, loss of miR‐146a leads to continuous bone accrual during aging as a result of unrestricted bone anabolism and intact Wnt signaling. Therefore, miR‐146a crucially controls the temporal facet of bone homeostasis. "microRNA-146a controls age-related bone loss" Saferding V, Hofmann M, Brunner JS, et al. Aging Cell. 2020 Nov;19(11):e13244. doi: 10.1111/acel.13244. click here to read the story

Read More
6 10, 2020

MedUni Wien “Researcher of the Month” Oktober 2020

2023-03-10T10:53:18+01:00October 6th, 2020|biomarker, Liver disease, microRNAs, Personalized medicine|Comments Off on MedUni Wien “Researcher of the Month” Oktober 2020

We want to congratulate Dr. Patrick Starlinger to his award “Researcher of the Month” for his work in cooperation with TAmiRNA GmbH, in Hepatology. "Predicting Postoperative Liver Dysfunction Based on Blood Derived MicroRNA Signatures." Hepatology. 2019 Jun;69(6):2636-2651. Click here for more information on TAmiRNA services Click here to read the story

Read More
1 10, 2020

Dr. Michael Nodine´s Spike-in technology is nominated for a Houska prize

2023-03-10T10:28:48+01:00October 1st, 2020|biomarker, microRNA, microRNA services, Personalized medicine, safety, test service|Comments Off on Dr. Michael Nodine´s Spike-in technology is nominated for a Houska prize

The “Houska“ Prize, awarded annually by the B&C Foundation, is Austria´s biggest private award for applied research. Dr. Michael Nodine, Gregor Mendel Institute of Molecular Plant Biology (GMI), was nominated for his work on the development of methods for nucleic acid quantification. A major issue they encountered was the lack of absolute quantification of small RNA levels, making the comparison between tissues difficult. To overcome this problem, Michael and his team, developed a set of synthetic small RNA Spike-Ins that could be added to these tissue samples. This technology allows us to accurately quantify the levels of different small RNAs that could play a role in several human diseases, ranging from cancer to cardiovascular disease. In 2019, GMI [...]

Read More
29 05, 2020

microRNAs as Promising Biomarkers of Platelet Activity in Antiplatelet Therapy Monitoring

2023-03-10T10:52:14+01:00May 29th, 2020|biomarker, biomarkers, microRNA, microRNAs, Personalized medicine, platelet activation, platelet-associated miRNAs, thrombomiR|Comments Off on microRNAs as Promising Biomarkers of Platelet Activity in Antiplatelet Therapy Monitoring

We want to draw your attention to the latest review of TAmiRNA and the King's College London, in Cardiovascular Diabetology. "microRNAs as Promising Biomarkers of Platelet Activity in Antiplatelet Therapy Monitoring." Krammer TL, Mayr M & Hackl M. Int. J. Mol. Sci. 2020, 21(10), 3477; doi.org/10.3390/ijms21103477 In this review, we explain the secretion of miRNAs upon platelet activation and discuss the potential use of platelet-related miRNAs as biomarkers for CVD and antiplatelet therapy monitoring, but also highlight remaining gaps in our knowledge and uncertainties regarding clinical utility. click here to read the story

Read More
24 02, 2020

TAmiRNA at SOT 2020, 15-19 March 2020, Anaheim, California, USA

2023-03-10T10:52:49+01:00February 24th, 2020|biomarker, biomarkers, drug development, drug discovery, liquid biopsies, LMD, microRNAs, Personalized medicine|Comments Off on TAmiRNA at SOT 2020, 15-19 March 2020, Anaheim, California, USA

The sequencing advance allows genome scale analysis of miRNAs and promises a more efficient discovery approach for safety biomarkers, enabling retrospective analysis. Dr. Kseniya Khamina, TAmiRNA research scientist, will deliver a presentation on ‘Next-generation sequencing pipeline for genome-scale analysis of circulating microRNAs as discovery approach for safety biomarkers’ (P338) during the Biomarkers Poster Session on Day Two, CC Exhibit Hall, of the meeting. The poster was co-authored by TAmiRNA and researchers from the Functional Genomics Center Zurich, Eli Lilly and Company and Merck & Co. Take advantage, meet Kseniya and discuss our latest developments and how TAmiRNA's products and services can assist your business or make an appointment NOW!

Read More
© Copyright TAmiRNA 2019 - 
 
Go to Top